LEDGER STEVEN A 4
4 · Serina Therapeutics, Inc. · Filed May 26, 2026
Research Summary
AI-generated summary of this filing
Serina Therapeutics (SER) CEO Steven Ledger Receives Option Grant
What Happened Steven A. Ledger, Chief Executive Officer of Serina Therapeutics (SER), received a grant/award of derivative securities covering 380,825 shares on 2026-05-21. The filing shows an acquisition price of $0.00 (no cash paid at grant), consistent with an options award rather than an open‑market purchase or sale.
Key Details
- Transaction type: Grant/Award (derivative securities, transaction code A)
- Transaction date: 2026-05-21; Form 4 filed 2026-05-26 (timely)
- Shares/units granted: 380,825 (acquisition price listed as $0.00)
- Shares owned after transaction: Not specified in the provided filing summary
- Notable footnote: Vesting described in footnote F1 — 12/48ths vest 12 months after the Vesting Commencement Date (one‑year cliff), then 1/48th vests each month thereafter until fully vested (i.e., typical four‑year schedule)
- No immediate sale or cashless exercise reported
Context This is a compensation-related option award for the CEO, not a market purchase or sale. Option grants do not necessarily indicate a near‑term market signal — they create potential future upside if the company’s stock appreciates and the options are exercised according to the vesting and exercise terms.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-05-21+380,825→ 380,825 totalExercise: $1.89Exp: 2036-05-21→ Common Stock (380,825 underlying)
Footnotes (1)
- [F1]Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.